Hemophilia patients' experience with marstacimab treatment
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This registry study follows people with hemophilia A or B who are taking marstacimab as their regular preventive treatment. It aims to understand how the medicine works in real life and how patients feel during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hemophilia A or B
- Your doctor has prescribed marstacimab to prevent bleeding episodes
- You are 12 years old or older
- You are able to attend follow-up visits for at least one month
- You can complete questionnaires about your health
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a medicine called marstacimab for people with hemophilia A or B. If you are already taking marstacimab or have a prescription for it, this study may help us learn more about how well it works.
This study looks at how a medicine called Marstacimab affects your body's natural anti-clotting protein (TFPI) in people with severe hemophilia A or B who are already taking it. It involves blood tests to see how well the treatment works.
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
This study uses ultrasound to check if joints that are currently healthy stay healthy in people with hemophilia A who are taking emicizumab (Hemlibra) as their regular treatment. It aims to see if this treatment helps prevent joint damage over time.
This Phase 3 study looks at how well and how safely marstacimab works over a longer follow-up period. You may join if you already finished a related parent study for hemophilia, and you can keep up with frequent visits and lab tests.
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.